

P21587.A05


REMARKS

The Examiner is respectfully requested to enter the foregoing amendment prior to examination of the above-identified patent application.

The amendments to the application have been made to correct typographical errors, and thus, should be considered to have been made for a purpose unrelated to patentability, and no estoppel should be deemed to attach thereto.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,
N. NISHIKAWA et al.


Bruce H. Bernstein
Reg. No. 29,027
Reg. No. 3/2/96

February 19, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

P21587.A05

APPENDIX

MARKED-UP COPY OF THE AMENDMENTS

Page 4, second full paragraph:

---Compounds which structurally relates to the compounds represented by the general formula (XXI) of the present invention are described in WO98/11895, WO98/06402, [EP746962] EP 749 962, U.S. Patent Nos. 5,708,187, 5,814,653, C. R. Heb. Seances Acad. Sic., 251, p.2728, 1960 and J. Phamacol. Exptl. Therap., 99, p. 450, 1950. However, these publications do not specifically disclose nor suggest the compounds of the present invention and the NPY antagonism thereof.---